Literature DB >> 15764047

Fluocinolone acetonide topical oil for scalp psoriasis.

M Pauporte1, H Maibach, N Lowe, M Pugliese, D J Friedman, H Mendelsohn, I Cargill, R Ramirez.   

Abstract

Numerous preparations that are available for the treatment of psoriasis of the scalp contain high potency steroids, such as betamethasone dipropionate lotion or clobetasol propionate solution. Of special interest is a currently marketed oil preparation that contains the steroid fluocinolone acetonide (0.01%), classified as low potency (Class 6) steroid. Because the combination of emollients in the vehicle base are present to aid in softening the stratum corneum and allow penetration of the steroid component into the lower skin layer, it was thought this preparation would be an efficient treatment for psoriasis of the scalp. This study was designed to demonstrate the efficacy, tolerance and safety of fluocinolone acetonide 0.01% in oil, compared to its vehicle, for the treatment of scalp psoriasis. This was a randomized, double-blind, vehicle-controlled multi-center study in patients with moderate to severe scalp psoriasis. At the completion of the treatment period (21 days) all signs of psoriasis had improved in both treatment groups, the improvements in the FA group being significantly greater compared to those in the vehicle-treated group. The results of the physician global assessments of improvement in the signs of psoriasis from baseline confirmed the findings. Significantly more patients in the FA group had a good or better improvement from baseline compared to the number in the vehicle-treated group. The results of this study conclusively show that FA in an oil base that aids in the softening of the skin and allows penetration of the steroid into the stratum corneum, is an effective treatment for psoriasis of the scalp. This study also showed that the vehicle alone causes an improvement in the signs of psoriasis, but that the addition of 0.1% of the low potency steroid, fluocinolone acetonide, leads to a significantly better improvement.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15764047     DOI: 10.1080/09546630410023566

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  8 in total

1.  Fluocinolone acetonide partially restores the mineralization of LPS-stimulated dental pulp cells through inhibition of NF-κB pathway and activation of AP-1 pathway.

Authors:  Zhongning Liu; Ting Jiang; Xinzhi Wang; Yixiang Wang
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 2.  Topical corticosteroid-induced skin atrophy: a comprehensive review.

Authors:  Laurent Barnes; Gurkan Kaya; Victoria Rollason
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.606

3.  Fluocinolone Acetonide Microemulsion in Combination with a Fractional Laser for the Treatment of Scalp Psoriasis.

Authors:  Voraphol Vejjabhinanta; Walaisiri Muangsiri; Pornpen Werawatganone
Journal:  AAPS PharmSciTech       Date:  2022-04-22       Impact factor: 3.246

Review 4.  Topical treatments for scalp psoriasis.

Authors:  Richard B Warren; Benjamin C Brown; Christopher E M Griffiths
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Topical treatments for scalp psoriasis.

Authors:  Justin Gabriel Schlager; Stefanie Rosumeck; Ricardo Niklas Werner; Anja Jacobs; Jochen Schmitt; Christoph Schlager; Alexander Nast
Journal:  Cochrane Database Syst Rev       Date:  2016-02-26

6.  Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review.

Authors:  Arnd Jacobi; Anke Mayer; Matthias Augustin
Journal:  Dermatol Ther (Heidelb)       Date:  2015-01-21

Review 7.  Use of Topical Corticosteroids in Dermatology: An Evidence-based Approach.

Authors:  Anupam Das; Saumya Panda
Journal:  Indian J Dermatol       Date:  2017 May-Jun       Impact factor: 1.494

8.  Efficacy and safety of fluocinolone acetonide 0.025% otic solution in patients with otic eczema: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Victoria Montoro; Carlos Asensio; Ángel Martínez; Juan Lorente; Francisco J Rodríguez; José Montojo; Javier Gavilanes; Pedro Sarría; Cristóbal Langdon; Eduard Prades
Journal:  J Int Med Res       Date:  2018-08-24       Impact factor: 1.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.